Toward the Development of a Protein: Non-protein Macromolecular Adjuvants

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N93019C00036
Agency Tracking Number: N43AI190036
Amount: $310,592.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: N/A
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4950 Research Park Way, LAWRENCE, KS, 66047-3944
DUNS: 080412808
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Erik Naylor
 (785) 550-8786
 whittier.sean@gmail.com
Business Contact
 Erik Naylor
Phone: (785) 550-8786
Email: whittier.sean@gmail.com
Research Institution
N/A
Abstract
An existing problem being faced in the development of new vaccines is the need for targeting bacterial infections that occur at mucosal sites such as the upper airway and the gastrointestinal tractOvercoming this problem will require the use of novel vaccine formulations andin particularthe use of novel immune enhancing agentsadjuvantsthat promote immune responses that are effective at mucosal sitesIn this studywe will explore the additive and potentially synergistic activities of two potential adjuvants for their ability to specifically induce a balanced immune response to a novel subunit vaccine designed to prevent infection by an enteric pathogenThe ability of the novel adjuvant to promote delivery of protein antigens to antigen presenting cells is expected to promote a robust balanced immune response that is effective against this and other pathogens that infect at mucosal sites

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government